Efficacy of Artemisia Pollen Specific Allergen Immunotherapy

Summary

Allergic rhinitis (AR) is a noninfectious inflammatory disease of the nasal mucosa mediated by immunoglobulin E (IgE) after exposure to allergens. Artemisia annua is one of the most important allergen that is responsible for seasonal AR in China during July and October. Allergen specific immunotherapy (AIT) is the only etiological treatment available for AR. The trial is a randomized, Open label, multicentred trial. A total of 150 subjects with allergic rhinitis caused by Artemisia pollen were recruited and randomized to the immunotherapy group and conversation drugs group.

Timeline

Start

2022-03-31

Primary completion

2024-10-15

Completion

2024-11-30

Publications

• Li J, Fang D, Ma T, Liu Y, Zhang X, Liu S, Wang C, Zhang L, Zhang Y. Effect of initiation treatment timing on efficacy of Artemisia Annua sublingual immunotherapy in patients with allergic rhinitis. World Allergy Organ J. 2026 Apr 8;19(4):101381. doi: 10.1016/j.waojou.2026.101381. eCollection 2026 Apr.

Drugs

Indications